---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: OptimUM-01"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: OptimUM-01. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 88 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence/optimum-01"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: OptimUM-01

<a id="heading-3.1.2"></a>

## 3.1.2 OptimUM-01

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### First-line cohort: safety and efficacy of darovasertib plus crizotinib in the phase 2 expansion

> “To report the safety and efficacy results from the phase II dose expansion portion of the OptimUM-01 trial for patients with metastatic uveal melanoma (mUM) treated in the first-line setting with the combination of the first-in-class, oral, targeted protein kinase C inhibitor darovasertib plus the MET-inhibitor crizotinib.”
> “Here, we present phase 2 results in first-line patients with mUM treated with darovasertib 300 mg twice a day and crizotinib 200 mg twice a day.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.1-2"></a>

#### Registry title and purpose of the basket study

> “A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions”
> “This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.”
> “Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.1-3"></a>

#### HLA-A∗02:01-positive expansion: analysis of participants treated with darovasertib plus crizotinib

> “This analysis focuses on the phase 2 expansion in HLA-A02:01-positive patients with mUM treated with darova+criz”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.1-4"></a>

#### First-line and pretreated cohorts: evaluation of the combination

> “This phase 1/2 study evaluated the combination in first line (1L) and pretreated MUM.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registry study dates

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2019-06-28” |
| Primary completion (estimated) | “2027-01-29” |
| Study completion (estimated) | “2027-06-15” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.2-2"></a>

#### Registry study sites

| Country | Quoted site |
| --- | --- |
| United States | “UCLA Medical Center” |
| United States | “San Francisco Oncology Associates” |
| United States | “SCRI - Denver” |
| United States | “University of Iowa” |
| United States | “Cancer Hematology Centers Western Michigan” |
| United States | “Columbia University Medical Center - Herbert Irving Pavilion” |
| United States | “Duke University Medical Center” |
| United States | “University of Cincinnati Cancer Center” |
| United States | “The Cleveland Clinic Foundation” |
| United States | “Sidney Kimmel Cancer Center at Thomas Jefferson University” |
| United States | “The Sarah Cannon Research Institute/Tennessee Oncology” |
| United States | “The University of Texas MD Anderson Cancer Center” |
| Australia | “Westmead Hospital” |
| Canada | “Princess Margaret Cancer Centre” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.2-3"></a>

#### First-line cohort publication: enrolling centers

| Country | Quoted institution |
| --- | --- |
| United States | “Sarah Cannon Research Institute Nashville, TN” |
| United States | “MD Anderson, Houston, TX” |
| United States | “Thomas Jefferson University Hospital, Philadelphia, PA” |
| United States | “Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA” |
| United States | “Duke University Medical Center, Durham, NC” |
| United States | “California Pacific Medical Center Research Institute, San Francisco, CA” |
| United States | “University of Cincinnati Medical Center, Cincinnati, OH” |
| United States | “Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI” |
| United States | “Cleveland Clinic, Cleveland, OH” |
| United States | “Sarah Cannon Research Institute at Healthone Denver, Denver, CO” |
| United States | “Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA” |
| United States | “Honor Health Research Institute, Scottsdale, AZ” |
| United States | “Florida Cancer Specialist—North, FL” |
| United States | “Florida Cancer Specialist—South, FL” |
| United States | “St Joseph Mosaic Life Care, St Joseph, MO” |
| United States | “Goshen Health Center for Cancer Care, Goshen, IN” |
| United States | “Columbia University Medical Center, New York Presbyterian Hospital, New York, NY” |
| United States | “The University of Texas MD Anderson Cancer Center, TX” |
| Australia | “Westmead and Blacktown Hospitals, University of Sydney and Melanoma Institute Australia” |
| Australia | “University of Queensland, Brisbane” |
| Canada | “Princess Margaret Cancer Centre, Departments of Medicine and Immunology, University of Toronto, Toronto” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.2-4"></a>

#### First-line cohort: data cutoff of May 28, 2025

> “As of the data cutoff for the analysis (May 28, 2025), the mean duration of exposure was 10 months for both darovasertib and crizotinib.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.2-5"></a>

#### HLA-A∗02:01-positive expansion: data extract date of March 23, 2026

> “Herein, we evaluated darova+criz among HLA-A02:01-positive patients enrolled in the expansion phase of the OptimUM-01 study (Data extract date of March 23, 2026)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “The ESMO update focuses on the Phase 2 expansion results from OptimUM-01 in HLA-A*02:01-positive mUM patients as of a cutoff date of March 23, 2026.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-3.1.2.2-6"></a>

#### First-line and pretreated cohorts: data cutoff of August 22, 2023

> “Reported data are preliminary and based on investigator review from an unlocked database for 68 patients as of the data analyses cutoff date of August 22, 2023.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### First-line cohort: phase 1/2, multicenter, open-label, dose-escalation and expansion design

> “OptimUM-01 was a phase I/II, multicenter, open-label, dose-escalation and expansion study, which evaluated monotherapy darovasertib and combination cohorts that included crizotinib in patients with mUM irrespective of HLA status (Appendix Fig A2).”
> “This analysis focuses on the phase 2 expansion in previously untreated patients who received darovasertib 300 mg twice a day in combination with crizotinib 200 mg twice a day.”
> “Results from other dosing cohorts of this trial will be published separately.”
> “The trial was approved by the institutional review board or independent ethics committee at each center, and all participants provided written informed consent.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.3-2"></a>

#### Registry design: nonrandomized, open-label, sequential assignment

| Study characteristic | Quoted record |
| --- | --- |
| Other study ID number | “IDE196-001” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.3-3"></a>

#### Registry: crizotinib combination dose optimization, crizotinib monotherapy cohort, and enrollment status by cohort

> “Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study.”
> “Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.”
> “As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.3-4"></a>

#### Registry: enrolling crizotinib combination expansion cohort of HLA-A∗02:01-positive participants with nested pharmacokinetic substudies

> “MUM patients (previously treated or treatment naive) with human leukocyte antigen (HLA)-A*02:01 positive status.”
> “Includes a nested PK sub-study with Pravastatin (~22 participants) to evaluate the impact of pravastatin PK profiles after continuous dosing of IDE196.”
> “Includes a nested PK Cocktail DDI sub-study (~15 participants) to evaluate the impact on the PK of bupripion, repaglinide, flurbiprofen, omeprazole, midazolam, dabigatran etexilate, and the exposures of the OAT3 biomarker PDA by IDE196 in combination with crizotinib.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.3-5"></a>

#### Combination dose escalation: 3 + 3 design followed by expansion

> “Dose escalation used a 3 + 3 design with 3 escalation cohorts, followed by expansion at 300 mg BID Daro + 200 mg BID Crizo.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-3.1.2.3-6"></a>

#### HLA-A∗02:01-positive expansion: study design as described in the poster

> “OptimUM-01 is a phase 1/2, multi-center, open-label, dose escalation and expansion study including patients with solid tumors harboring GNAQ/11 mutations”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### First-line cohort: key eligibility criteria

> “Patients were required to be age 18 years or older and have a histologic or cytologic confirmation of uveal melanoma. Eligible patients had metastatic disease that was measurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and adequate organ function. This analysis is specific to individuals who had not received previous therapy for mUM.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-2"></a>

#### Inclusion criteria, including documentation required for treatment-naive HLA-A∗02:01-positive participants

> “Patient must be age 18 years and older and able to provide written informed consent”
> “Metastatic uveal melanoma: histologic or cytologic confirmation of metastatic uveal melanoma. Metastatic disease may be treatment-naïve or have progressed on or after most recent therapy. If the most recent therapy was an immune-oncology agent, progressive disease must be confirmed.”
> “If a patient is treatment-naïve and human leukocyte antigen (HLA)-A*02:01–positive,”
> “documentation is required to provide rationale why treatment with tebentafusp is not the ideal first-line treatment approach or of the patient's intolerance to tebentafusp.”
> “To be enrolled in the HLA-A*02:01–positive cohort, HLA status must be documented by test results from a College of American Pathologists/ Clinical Laboratory Improvement Amendments-certified laboratory.”
> “Eastern Cooperative Oncology Group performance status ≤1 and expected life expectancy of >3 months”
> “Adequate contraceptive measures for nonsterilized male and female patients of childbearing potential”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-3"></a>

#### Additional inclusion criteria for the crizotinib combination

> “Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks before initiation of crizotinib”
> “Patients with preexisting peripheral neuropathy can be included if it is grade 1 or lower, before initiation of crizotinib”
> “Accessible lesion(s) that permit a total of at least two biopsies without unacceptable risk of a significant procedural complication.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-4"></a>

#### Exclusion criteria

> “Previous treatment with a protein kinase C inhibitor”
> “Known microsatellite instability-high/deficient mismatch repair tumors that have not previously received immune checkpoint inhibitors”
> “Known symptomatic brain metastases”
> “Adverse events from prior anticancer therapy that have not resolved”
> “Known acquired immunodeficiency syndrome (AIDS)–related illness, hepatitis B virus, or hepatitis C virus”
> “Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect”
> “Treatment with prohibited medications that cannot be discontinued before study entry”
> “For patients receiving darovasertib powder-in-capsule formulation or crizotinib, allergy to mammalian meat products and gelatin”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-5"></a>

#### Additional exclusion criteria for the crizotinib combination

> “Prior therapy directly targeting ALK, MET, or ROS1”
> “History of pneumonitis or interstitial lung disease”
> “History of thromboembolic or cerebrovascular events ≤12 weeks before first dose of study treatment”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.4-6"></a>

#### Registry: exclusion criteria of the pravastatin pharmacokinetic substudy

> “Taken any dose of statin or inhibitor of organic anion transporting polypeptide within 7 days prior to enrollment in the study and cannot refrain from them through C2D1”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.4-7"></a>

#### HLA-A∗02:01-positive expansion: eligibility criteria

> “Eligibility criteria included RECIST v1.1 measurable disease, ECOG status 0-1, and adequate organ function”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.4-8"></a>

#### First-line and pretreated cohorts: eligibility criteria

> “Eligibility included RECIST 1.1 measurable disease, ECOG 0-1 and adequate organ function.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### First-line cohort: dose selection, darovasertib run-in, and continuous 28-day cycles

> “The recommended dose of crizotinib 200 mg twice a day used in combination with darovasertib 300 mg twice a day for the phase 2 expansion was selected based on a favorable benefit-risk profile from the earlier dose-escalation and dose-optimization portion of the study.”
> “The first treatment cycle had a 7-day darovasertib treatment run-in followed by continuous dosing of the combination over a 28-day cycle.”
> “Patients remained on treatment until discontinuation due to toxicity or until disease progression and received tumor assessments every 8 weeks; treatment beyond progression was permitted for patients who were deriving clinical benefit.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.5-2"></a>

#### Registry interventions: oral twice-daily dosing in 28-day cycles

> “IDE196 dosed orally, twice daily for each 28-day cycle”
> “Crizotinib dosed orally, twice daily for each 28-day cycle”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.5-3"></a>

#### First-line and pretreated cohorts: expansion dose of darovasertib 300 mg and crizotinib 200 mg twice a day

> “The reported Phase 2 clinical data are based on evaluable first-line and any-line patients enrolled in the darovasertib and crizotinib combination study at the expansion dose of 300 mg twice-a-day darovasertib and 200 mg twice-a-day crizotinib as of September 22, 2022.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-3.1.2.5-4"></a>

#### Selection of the combination expansion dose for potential registrational studies

> “IDEAYA has selected a darovasertib and crizotinib combination expansion dose to support potential registrational studies.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using RECIST v1.1 Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### First-line cohort: investigator-assessed RECIST v1.1 response and imaging schedule

> “Tumor response was assessed by radiologic imaging determined by the investigator according to RECIST, version 1.1.”
> “Tumor assessments were performed at Cycle 3 Day 1 (±7 days) and every two cycles thereafter (±7 days).”
> “For patients who remained on study for longer than 13 cycles, tumor imaging evaluations were performed on Cycle 16 Day 1 (±7 days), and every three cycles thereafter until disease progression (±7 days).”
> “Safety was evaluated by ongoing monitoring of AEs, clinical laboratory tests, electrocardiograms, and changes in vital signs.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-2"></a>

##### First-line cohort: end points, with overall survival as an exploratory end point

> “Study end points included safety, objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).”
> “Study design. Overall survival is an exploratory end point in this trial.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-3"></a>

##### First-line cohort: definitions of objective response, disease control, and duration of response

> “ORR was defined as the proportion of patients with best response of complete response (CR) or partial response (PR) as defined by RECIST, version 1.1. Confirmation of response was required.”
> “DCR was defined as the proportion of patients who have achieved a best response of CR or PR, or stable disease (SD) lasting for at least 8 weeks after the first assessment of CR, PR, or SD.”
> “DOR was defined as the time of first occurrence of a documented response (CR or PR) until the date of disease progression per RECIST 1.1 or death, whichever occurred first.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-4"></a>

##### First-line cohort: definitions of progression-free survival, overall survival, and molecular response

> “PFS was defined as the number of days from first day of treatment to the date of first documented disease progression or date of death, whichever occurred first, for patients who received at least one dose of study treatment.”
> “OS was defined as the number of days from first day of treatment to the date of death.”
> “A confirmed molecular partial response was defined as a ≥50% reduction from baseline in the molecular biomarker (cfDNA), confirmed by a second measurement obtained at least 4 weeks after the initial response.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.6.1-5"></a>

##### Registry primary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Dose-limiting toxicity | “Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” |
| Adverse events | “Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “Approx. 8 months” |
| Maximum tolerated dose | “Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” |
| Recommended phase 2 dose | “Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib” | “Approx. 6 months” |
| Objective response rate in dose expansion | “Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment” | “Approx. 8 months” |
| Duration of response in dose expansion | “Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment” | “Approx. 8 months” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.6.1-6"></a>

##### Registry secondary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Progression-free survival | “Progression Free Survival (PFS) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment” | “Approx. 18 months” |
| Objective response rate by prior treatment status | “Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts and by prior treatment status (pretreated or treatment naive) by Investigator response assessment” | “Approx. 18 months” |
| Duration of response by prior treatment status | “Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by prior treatment status (pretreated or treatment naive) by Investigator response assessment” | “Approx. 18 months” |
| Disease control rate | “Disease Control Rate (DCR) by Investigator” | “Approx. 18 months” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.6.1-7"></a>

##### HLA-A∗02:01-positive expansion: end points

> “Endpoints included PFS, OS, and safety as well as objective response rate (ORR), duration of response (DOR), and disease control rate (DCR)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.6.1-8"></a>

##### FDA guidance: objective response rate as a direct measure of antitumor activity evaluable in a single-arm study

> “ORR is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period.”
> “Generally, the FDA has defined ORR as the sum of partial responses plus CRs.  When defined in this manner, ORR is a direct measure of a drug antitumor activity, which can be evaluated in a single-arm study.”
> “Stable disease should not be a component of ORR.  Stable disease can reflect the natural history of disease, whereas tumor reduction is a direct therapeutic effect.”
> “The significance of ORR is assessed by its magnitude and duration, and the percentage of CRs.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.2.6.1-9"></a>

##### FDA guidance: single-arm studies, accelerated approval, and time-to-event end points

> “In settings where there is no available therapy and where major tumor regressions can be presumed to be attributed to the tested drug, the FDA has sometimes accepted ORR and response duration observed in single-arm studies as substantial evidence supporting accelerated approval.”
> “Single-arm trials do not adequately characterize time-to-event endpoints such as overall survival, DFS (and EFS), TTP, or PFS.”
> “Because ORR is directly attributable to drug effect, single-arm trials conducted in patients with refractory tumors where no available therapy exists provide an accurate assessment of ORR.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.2.6.1-10"></a>

##### IDE196 monotherapy: FDA End-of-Phase 1 feedback on a single-arm design with response rate as the primary endpoint

> “FDA EOP1 meeting minutes indicate that the proposed single-arm Phase 2 IDE196 clinical trial may be adequate to support a new drug application (NDA) seeking Accelerated Approval of IDE196 monotherapy for the treatment of MUM”
> “This Phase 2 clinical trial will target enrollment of 60 evaluable MUM patients with the primary endpoint of overall response rate (ORR) as determined by blinded independent central review (BICR)”

Source: [IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019)](https://media.ideayabio.com/2019-10-31-IDEAYA-Biosciences-Reports-End-of-Phase-1-Meeting-with-FDA-for-IDE196-Confirms-Acceptability-of-Single-Arm-Trial-Design-for-Potential-Phase-2-Registration-Enabling-Study-in-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### First-line cohort: 44 participants enrolled and treated, 41 evaluable for response

> “There were 44 patients with no prior systemic therapy for mUM who were enrolled and received darovasertib-crizotinib.”
> “The waterfall plot with a percent change from baseline in the sum of longest diameters for each evaluable patient (n = 41) is displayed in Figure 1.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.1-2"></a>

##### Registry: estimated enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (estimated), all cohorts of the basket study | “336” |

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-3.1.2.7.1-3"></a>

##### Pretreated cohort, data cutoff of November 25, 2021: target enrollment of the combination arm and participants enrolled at the expansion dose

> “The companies have agreed to support a target enrollment of approximately 40 patients into the ongoing Phase 1/2 clinical combination arm in MUM.”
> “At the time of the data and analyses cutoff on November 25, 2021, twenty-two (22) heavily pre-treated (91% with prior therapies, and 59% with 2 or more prior therapies) MUM patients had enrolled in the darovasertib and crizotinib combination arm at the expansion dose, with sixteen (16) evaluable patients who have received one or more tumor scans and 6 patients who are awaiting their 1st tumor scan.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.2.7.1-4"></a>

##### First-line and pretreated cohorts, data cutoff of March 8, 2023: safety population of 68 and per-protocol efficacy population of 63 participants

> “At 08Mar2023 data cut-off, of 68 MUM pts treated at the expansion dose (safety population (SP)) as of September 2022, 63 were evaluable for response (per-protocol efficacy population (PPEP)).”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-3.1.2.7.1-5"></a>

##### HLA-A∗02:01-positive expansion: 101 participants treated

> “Overall, 101 HLA-A02:01-positive patients were treated (Table 1), with a median follow-up of 10.4 months for overall survival”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### First-line cohort: safety population and efficacy-evaluable population

> “Analysis populations included the safety population, defined as all patients who received at least one dose of the study drug. Patients who received at least one dose of the study drug and had at least one postbaseline tumor assessment were considered efficacy-evaluable (ie, efficacy evaluable population) for ORR, disease control rate (DCR), and duration of response (DOR). PFS and OS were reported for the full safety population.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-2"></a>

##### First-line cohort: three participants excluded from the response analysis

> “Two patients who discontinued treatment before postbaseline tumor assessments (one due to AE of sudden death and another due to patient decision) and one ongoing patient who had not yet had a postbaseline tumor assessment were excluded from this analysis.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-3"></a>

##### First-line cohort: descriptive analysis without formal hypothesis testing

> “There was no formal hypothesis testing prespecified for this analysis. All results were summarized descriptively.”
> “Time-to-event end points were analyzed using the Kaplan-Meier method to estimate survival curves and medians; corresponding 95% CI for median estimates were calculated using Brookmeyer-Crowley method.”
> “CI is calculated using Clopper-Pearson method.”
> “Treatment-emergent AEs (TEAEs) were summarized descriptively by category: all AEs, grade ≥3 AEs, treatment-related AEs (TRAEs), AEs leading to study drug reductions or discontinuations, and serious AEs (SAEs).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-4"></a>

##### First-line cohort: censoring rules for progression-free survival

> “Patients who discontinued the study and were lost to follow-up without a known date of progression or death due to any cause on or before the cutoff date were censored at the date of their last available tumor assessment (or, if no tumor assessment was performed after the baseline visit, at the date of first dose of study drug plus 1 day).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.7.2-5"></a>

##### HLA-A∗02:01-positive expansion: efficacy-evaluable population and all-enrolled population

> “Response assessments utilized the efficacy evaluable population which includes all patients had ≥3 post-baseline assessments or who discontinued treatment.”
> “PFS and OS assessments utilized the all enrolled Population which include all patients who had ≥1 dose of treatment.”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### First-line cohort: discontinuations due to treatment-emergent adverse events

> “TEAEs leading to discontinuation occurred in three patients (6.8%), with each discontinuation attributed to a different AE (1 patient each with cancer fatigue, peripheral edema, and grade 5 AE).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.1-2"></a>

##### HLA-A∗02:01-positive expansion: discontinuations due to adverse events

> “treatment discontinuations due to AEs occurred in 15 patients (14.9%), 9 of which were considered treatment-related”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.1-3"></a>

##### First-line and pretreated cohorts, data cutoff of August 22, 2023: duration of treatment and participants continuing treatment

> “With approximately 5.5 months of additional follow-up from the previous data analysis cut-off date (March 8, 2023 to August 22, 2023), now approximately 30% of any-line MUM patients have been on treatment greater than one year and multiple patients with confirmed PRs by RECIST 1.1 have been on treatment greater than 24 months, with the potential for further enhancement on the duration of treatment (DOT) analysis as approximately 20% (13 out of 63 evaluable patients) of any-line MUM patients are continuing on treatment.”
> “Five patients (7%) discontinued treatment with darovasertib and crizotinib combination due to a drug-related adverse event.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### First-line cohort: baseline characteristics of 44 participants

| Characteristic | First-line cohort, N = 44 |
| --- | --- |
| Age, median years (range) | “64.5 (21, 80)” |
| Age less than 65 years, No. (%) | “22 (50.0)” |
| Female, No. (%) | “21 (47.7)” |
| Male, No. (%) | “23 (52.3)” |
| Race White, No. (%) | “41 (93.2%)” |
| Race Asian, No. (%) | “1 (2.3%)” |
| Race other or not reported, No. (%) | “2 (4.5%)” |
| ECOG PS 0, No. (%) | “27 (61.4)” |
| ECOG PS 1, No. (%) | “17 (38.6)” |
| Baseline LDH normal, No. (%) | “29 (65.9)” |
| Baseline LDH above ULN, No. (%) | “14 (31.8)” |
| Baseline LDH more than 2× ULN, No. (%) | “7 (15.9)” |
| Largest metastatic lesion 3.0 cm or less, No. (%) | “24 (54.5)” |
| Largest metastatic lesion 3.1 to 8.0 cm, No. (%) | “15 (34.1)” |
| Largest metastatic lesion 8.1 cm or more, No. (%) | “4 (9.1)” |
| Metastases hepatic only, No. (%) | “23 (52.3)” |
| Metastases extrahepatic only, No. (%) | “2 (4.5)” |
| Metastases hepatic and extrahepatic, No. (%) | “18 (40.9)” |
| HLA-A∗02:01 negative, No. (%) | “30 (68.2)” |
| HLA-A∗02:01 positive, No. (%) | “12 (27.3)” |
| HLA-A∗02:01 unknown, No. (%) | “2 (4.5)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.2-2"></a>

##### First-line cohort: high-risk features and HLA testing at enrollment

> “Baseline prognostic features in this patient population revealed that the percentage of patients with the largest metastatic lesion of > 3 cm (>M1a) was 43.2%.”
> “Overall, 27.3% of patients were HLA-A*02:01–positive and 68.2% were HLA-A*02:01–negative; HLA status was unknown for approximately 5% of patients because HLA testing was not routinely performed at the time that some patients were enrolled.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.2-3"></a>

##### First-line cohort: performance status compared by the sponsor with an earlier registrational study

> “The proportion of patients with ECOG PS 1 in the OptimUM-01 study is approximately two times higher than an earlier published registrational study in mUM.”

Source: [IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025)](https://media.ideayabio.com/2025-10-20-IDEAYA-Biosciences-Reports-Positive-Median-Overall-Survival-Data-from-Phase-2-Trial-of-the-Darovasertib-and-Crizotinib-Combination-in-First-line-Metastatic-Uveal-Melanoma-at-the-2025-Society-for-Melanoma-Research-Congress)

<a id="topic-3.1.2.8.2-4"></a>

##### HLA-A∗02:01-positive expansion: baseline characteristics of treatment-naive and overall populations

| Characteristic | Treatment-naive, N = 13 | Overall, N = 101 |
| --- | --- | --- |
| Age, median years (range) | “65.0 (21, 81)” | “66.0 (21, 81)” |
| Female, n (%) | “7 (53.8)” | “44 (43.6)” |
| Race White, n (%) | “13 (100.0)” | “95 (94.1)” |
| ECOG PS 0, n (%) | “6 (46.2)” | “66 (65.3)” |
| ECOG PS 1, n (%) | “7 (53.8)” | “35 (34.7)” |
| Baseline LDH at or below ULN, n (%) | “7 (53.8)” | “36 (35.6)” |
| Baseline LDH above ULN and below 2× ULN, n (%) | “4 (30.8)” | “43 (42.6)” |
| Baseline LDH 2× ULN or higher, n (%) | “2 (15.4)” | “22 (21.8)” |
| Metastases hepatic only, n (%) | “8 (61.5)” | “51 (50.5)” |
| Metastases extrahepatic only, n (%) | “2 (15.4)” | “12 (11.9)” |
| Metastases hepatic and extrahepatic, n (%) | “3 (23.1)” | “38 (37.6)” |
| No prior lines of therapy, n (%) | “13 (100)” | “13 (12.9)” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

| Prior lines of therapy | Overall, N = 101, n (%) |
| --- | --- |
| One prior line of therapy | “20 (19.8)” |
| Two or more prior lines of therapy | “67 (66.3)” |
| Not recorded, previously treated | “1 (1.0)” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.2-5"></a>

##### HLA-A∗02:01-positive expansion: prior systemic therapy, including second-line treatment after tebentafusp

> “Most patients (88/101) had received prior systemic therapy for mUM: 13 patients had no prior systemic therapies , and 15 patients received darova+criz in the second line setting after prior tebentafusp as the first-line therapy”
> “Elevated baseline LDH level was present in 64.4%, with 21.8% of patients with an LDH level that was 2x upper limit of normal or higher”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.2-6"></a>

##### First-line and pretreated cohorts, per-protocol efficacy population: tumor burden and HLA-A∗02:01 status

> “The PPEP had a large tumor burden: 66% with largest metastatic lesion > 3cm, 64% with hepatic + extrahepatic disease, & 60% with elevated LDH.”
> “HLA-A2*02:01 status (n=51 tested): 63% neg., 37% pos.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### First-line cohort, efficacy-evaluable population of 41 participants: response, duration of response, and disease control

| Outcome | First-line cohort, N = 41 |
| --- | --- |
| Objective response rate, No. (%) | “14 (34.1)” |
| Objective response rate, 95% CI | “20.1 to 50.6” |
| Best overall response CR, No. (%) | “0 (0.0)” |
| Best overall response PR, No. (%) | “14 (34.1)” |
| Best overall response SD, No. (%) | “23 (56.1)” |
| Best overall response PD, No. (%) | “4 (9.8)” |
| Duration of response, median months | “9.0” |
| Duration of response, 95% CI | “3.8 to 12.0” |
| Time to response, median months | “2.0” |
| Disease control rate at 8 weeks, No. (%) | “37 (90.2)” |
| Disease control rate at 8 weeks, 95% CI | “76.9 to 97.3” |
| Disease control rate at 26 weeks, No. (%) | “22 (53.7)” |
| Disease control rate at 26 weeks, 95% CI | “37.4 to 69.3” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Confirmed objective tumor response as assessed by investigator per RECIST 1.1.”
> “Efficacy-evaluable population includes all patients who received at least one dose of study drug and have at least one postbaseline tumor assessment.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-2"></a>

##### First-line cohort: tumor shrinkage

> “Most patients treated with darovasertib-crizotinib experienced evidence of tumor shrinkage.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “A DCR of 90% (37/41) was also observed, with 85% (35/41) of patients achieving 'any reduction' in target lesions.”

Source: [IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025)](https://media.ideayabio.com/2025-10-20-IDEAYA-Biosciences-Reports-Positive-Median-Overall-Survival-Data-from-Phase-2-Trial-of-the-Darovasertib-and-Crizotinib-Combination-in-First-line-Metastatic-Uveal-Melanoma-at-the-2025-Society-for-Melanoma-Research-Congress)

<a id="topic-3.1.2.8.3-3"></a>

##### First-line cohort, safety population: progression-free survival and overall survival at a median follow-up of 25 months

> “With a median study follow-up of 25 months (time from first treatment to data extraction), the median PFS was 7.0 months (95% CI, 3.8 to 7.7; Fig 2).”
> “The PFS rates at 6 months and 12 months were 52% and 28%, respectively.”
> “A median OS of 21.1 months (95% CI, 12.5 to 27.1) was observed.”
> “OS was analyzed using the safety population, which is defined as all patients who had at least one dose of study drug.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-4"></a>

##### First-line cohort: progression-free survival and overall survival with confidence intervals as stated in the abstract

> “The median PFS and OS were 7.0 months (95% CI, 5.0 to 8.3) and 21.1 months (95% CI, 11.9 to 20.7), respectively.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-5"></a>

##### First-line cohort: confirmed response by HLA-A∗02:01 status

| Outcome | HLA-A∗02:01 positive, n = 10 | HLA-A∗02:01 negative, n = 29 |
| --- | --- | --- |
| Objective response rate, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Objective response rate, 95% CI | “3.7 to 65.2” | “15.3 to 50.8” |
| Best overall response PR, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Best overall response SD, No. (%) | “7 (70.0)” | “16 (55.2)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (13.8)” |
| Disease control rate, No. (%) | “10 (100.0)” | “25 (86.2)” |
| Disease control rate, 95% CI | “NA” | “68.3 to 96.1” |
| Duration of response, median months | “10.15” | “9.03” |
| Duration of response, 95% CI | “3.75 to NE” | “1.94 to 9.03” |
| Time to response, median months | “3.7” | “1.9” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-6"></a>

##### First-line cohort: response in HLA-A∗02:01-positive participants as stated in the discussion

> “The preliminary results in the subset of HLA-A*02:01–positive treatment-naïve patients with mUM suggest that the observed ORR of 40% with darovasertib-crizotinib, if validated in a larger patient sample, could be especially meaningful in those presenting with bulky liver metastasis or extrahepatic disease where initial tumor shrinkage may be important to relieve associated symptoms or resulting organ dysfunction.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-7"></a>

##### First-line cohort: response by baseline LDH

| Outcome | LDH at or below ULN, n = 28 | LDH above ULN to 2× ULN, n = 7 | LDH above 2× ULN, n = 6 |
| --- | --- | --- | --- |
| Objective response rate, No. (%) | “8 (28.6)” | “2 (28.6)” | “4 (66.7)” |
| Objective response rate, 95% CI | “13.2 to 48.7” | “3.7 to 71.0” | “22.3 to 95.7” |
| Best overall response SD, No. (%) | “17 (60.7)” | “4 (57.1)” | “2 (33.3)” |
| Best overall response PD, No. (%) | “3 (10.7)” | “1 (14.3)” | “0 (0.0)” |
| Disease control rate, No. (%) | “25 (89.3)” | “6 (85.7)” | “6 (100)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-8"></a>

##### First-line cohort: response by tumor burden (largest metastatic lesion)

| Outcome | 3 cm or less, n = 23 | Above 3 cm to 8 cm, n = 15 | Above 8 cm, n = 3 |
| --- | --- | --- | --- |
| Objective response rate, No. (%) | “9 (39.1)” | “4 (26.7)” | “1 (33.3)” |
| Objective response rate, 95% CI | “19.7 to .61.5” | “7.8 to 55.1” | “0.8 to 90.6” |
| Best overall response SD, No. (%) | “14 (60.9)” | “7 (46.7)” | “2 (66.7)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (26.7)” | “0 (0.0)” |
| Disease control rate, No. (%) | “23 (100.0)” | “11 (73.3)” | “3 (100.0)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Outcomes were evaluated across LDH subgroups and baseline tumor burden, and responses were observed in all categories (Appendix Table A5).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-9"></a>

##### First-line cohort: molecular response in circulating cell-free DNA

> “Among the patients with reported GNAQ/11 mutations from tumor tissue (n = 20), plasma was tested and all patients had detectable cfDNA at baseline (Appendix Fig A3).”
> “Among these, 95% (19/20) demonstrated a molecular response with > 50% reduction in detectable cfDNA from baseline.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.3-10"></a>

##### HLA-A∗02:01-positive expansion: response, progression-free survival, and overall survival in treatment-naive and overall populations

| Outcome | Treatment-naive, N = 13 | Overall, N = 101 |
| --- | --- | --- |
| Objective response rate, n/N (%) | “4/11 (36.4)” | “19/86 (22.1)” |
| Objective response rate, 95% CI | “10.9, 69.2” | “13.9, 32.3” |
| Confirmed best overall response CR, n/N (%) | “0/11 (0.0)” | “0/86 ( 0.0)” |
| Confirmed best overall response SD, n/N (%) | “6/11 (54.5)” | “49/86 (57.0)” |
| Confirmed best overall response PD, n/N (%) | “0/11 (0.0)” | “9/86 (10.5)” |
| Confirmed best overall response not evaluable, n/N (%) | “1/11 (9.1)” | “9/86 (10.5)” |
| Disease control rate, n/N (%) | “10/11 (90.9)” | “69/86 (80.2)” |
| Median progression-free survival, 95% CI | “3.6, 19.6” | “3.7, 6.8” |
| Median overall survival, 95% CI | “8.9, NE” | “9.8, 26.3” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “The confirmed ORR was 36.4% in treatment-naïve patients and 22.1% in overall population (Table 2)”
> “The median PFS in treatment-naïve and overall population were 7.4 months (95%CI: 3.6-19.6) and 5.4 months (95%CI: 3.7-6.8), respectively (Table 2; Figure 2)”
> “The median OS was 27.1 months (95%CI: 8.9, not evaluable) and 13.4 months (95%CI: 9.8, 26.3) in treatment-naïve and overall populations, respectively (Table 2; Figure 3)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.3-11"></a>

##### HLA-A∗02:01-positive expansion: second-line participants after tebentafusp

> “In second-line patients following tebentafusp, the confirmed ORR, median PFS, and median OS was 35.7%, 5.7 months (95%CI: 3.7, not evaluable), and 12.1 months (95%CI: 9.8, not evaluable), respectively”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

| Outcome | Prior tebentafusp (second line), N = 15 |
| --- | --- |
| Objective response rate, n/N | “(5/14)” |
| Objective response rate, 95% CI | “12.8-64.9” |
| Disease control rate, % | “85.7%” |
| Disease control rate, n/N | “(12/14)” |
| Median duration of response | “5.6 mos” |
| Median progression-free survival, 95% CI | “3.65-NE” |
| Median overall survival, 95% CI | “9.79-NE” |

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-3.1.2.8.3-12"></a>

##### HLA-A∗02:01-negative participants of OptimUM-01 as reported for comparison in the HLA-A∗02:01-positive expansion poster

| Outcome | HLA-A∗02:01 negative, treatment-naive, N = 29 | HLA-A∗02:01 negative, overall, N = 61 |
| --- | --- | --- |
| Objective response rate, n/N (%) | “9/29 (31.0)” | “16/61 (26.2)” |
| Objective response rate, 95% CI | “15.3, 50.8” | “15.8, 39.1” |
| Disease control rate, n/N (%) | “25/29 (86.2)” | “53/61 (86.9)” |
| Median progression-free survival, 95% CI | “3.7, 9.2” | “5.0, 7.8” |
| Median overall survival, 95% CI | “12.0, 23.8” | “11.7, 20.7” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “Efficacy results with darova+criz treatment among HLA-A02:01-positive patients was generally consistent to those for HLA-A02:01-negative patients enrolled in the OptimUM-01 study in both treatment-naïve patients and overall population (Table 3)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### First-line cohort: dose intensity

> “Mean percent cumulative dose intensity was 84.9% for darovasertib and 80.0% for crizotinib.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “The median dose intensity for darovasertib and crizotinib was 92.6% and 88.0%, respectively”

Source: [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.5-2"></a>

##### First-line cohort: treatment-emergent adverse event summary

| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
| --- | --- | --- |
| Any AE | “44 (100)” | “23 (52.3)” |
| Serious AE | “9 (20.5)” | “8 (18.2)” |
| AE leading to discontinuation | “3 (6.8)” | “1 (2.3)” |
| AEs related to darovasertib leading to reduction | “3 (6.8)” | “0” |
| AEs related to crizotinib leading to reduction | “4 (9.1)” | “1 (2.3)” |
| Diarrhea | “42 (95.5)” | “1 (2.3)” |
| Nausea | “37 (84.1)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “23 (52.3)” | “0” |
| Dermatitis acneiform | “20 (45.5)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “18 (40.9)” | “0” |
| Constipation | “13 (29.5)” | “1 (2.3)” |
| Dizziness | “13 (29.5)” | “1 (2.3)” |
| Decreased appetite | “11 (25.0)” | “0” |
| Alanine aminotransferase increased | “9 (20.5)” | “2 (4.5)” |
| Headache | “9 (20.5)” | “0” |
| Aspartate aminotransferase increased | “8 (18.2)” | “1 (2.3)” |
| Cough | “8 (18.2)” | “0” |
| Dyspnea | “8 (18.2)” | “0” |
| Hypophosphatemia | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Anemia | “7 (15.9)” | “0” |
| Blood alkaline phosphatase increased | “7 (15.9)” | “0” |
| Dysgeusia | “7 (15.9)” | “0” |
| Blood creatinine increased | “6 (13.6)” | “0” |
| COVID-19 | “6 (13.6)” | “0” |
| Generalized edema | “6 (13.6)” | “1 (2.3)” |
| Hypokalemia | “6 (13.6)” | “2 (4.5)” |
| Pruritus | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Vision blurred | “6 (13.6)” | “2 (4.5)” |
| Blood lactate dehydrogenase increased | “5 (11.4)” | “0” |
| Cancer fatigue | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Gastroesophageal reflux disease | “5 (11.4)” | “0” |
| Iron deficiency anemia | “5 (11.4)” | “3 (6.8)” |
| Periorbital edema | “5 (11.4)” | “0” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Other ≥ grade 3 AEs occurring in >5% of patients: pulmonary embolism (9.1%). 3 patients had ≥ grade 3 AEs leading to treatment discontinuation (cancer fatigue, edema peripheral, and sudden death).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-3"></a>

##### First-line cohort: most common adverse events, grade 3 or higher events, serious adverse events, and deaths

> “Overall, all participants experienced at least one AE during the trial. The most common TEAEs (Table 2) and TRAEs (Appendix Table A1) were diarrhea (treatment-emergent: 95.5%; treatment-related: 90.0%), nausea (84.1%; 79.5%), peripheral edema (61.4%; 61.4%), and vomiting (52.3%; 47.7%).”
> “Grade 3 or greater TEAEs were experienced by 52.3% of participants (Table 2). The most common grade 3 or greater AEs were pulmonary embolism (9.1%) and iron deficiency anemia (6.8%). Treatment-emergent SAEs occurred in 20.5% of patients, with the most common being pulmonary embolism (2 patients [4.5%]; Appendix Tables A2 and A3).”
> “Two patients (4.5%) experienced grade 5 AEs, one of which was unrelated to study treatment (extensive liver disease with malignant ascites) and one of which was deemed possibly related to study treatment but was more likely the result of multiple contributing factors in a patient with advanced metastatic disease, such as worsening ascites, fluid imbalance, and electrolyte disturbances.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-4"></a>

##### First-line cohort: most common adverse events as stated in the abstract

> “The most common adverse events (AEs) were diarrhea (95.2%), nausea (84.1%), peripheral edema (61.4%), and vomiting (52.3%).”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-5"></a>

##### First-line cohort: dose reductions and dose holds

> “AEs related to darovasertib leading to dose reduction occurred in three patients (6.8%; one patient each with diarrhea, fatigue, and orthostatic hypotension). AEs related to crizotinib leading to dose reduction occurred in four patients (9.1%; two patients with diarrhea, and one each with fatigue and neutropenia). Thirty patients (68.2%) had at least one dose hold, with 21 having their first dose hold due to an AE and the rest for other reasons.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-6"></a>

##### First-line cohort: treatment-related adverse event summary

| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
| --- | --- | --- |
| Treatment-related AE | “43 (97.7)” | “12 (27.3)” |
| Treatment-related serious AE | “4 (9.1)” | “3 (6.8)” |
| Treatment-related AE leading to discontinuation | “2 (4.5)” | “1 (2.3)” |
| Diarrhea | “40 (90.9)” | “1 (2.3)” |
| Nausea | “35 (79.5)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “21 (47.7)” | “0” |
| Dermatitis acneiform | “19 (43.2)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “17 (38.6)” | “0” |
| Dizziness | “12 (27.3)” | “1 (2.3)” |
| Decreased appetite | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Constipation | “7 (15.9)” | “0” |
| Aspartate aminotransferase increased | “6 (13.6)” | “0” |
| Dysgeusia | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Alanine aminotransferase increased | “5 (11.4)” | “1 (2.3)” |
| Anemia | “5 (11.4)” | “0” |
| Blood alkaline phosphatase increased | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Generalized edema | “5 (11.4)” | “0” |
| Hypophosphatemia | “5 (11.4)” | “0” |
| Periorbital edema | “5 (11.4)” | “0” |
| Pruritus | “5 (11.4)” | “0” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-7"></a>

##### First-line cohort: treatment-emergent serious adverse events

| Serious adverse event | Overall population, N = 44, No. (%) |
| --- | --- |
| Any serious adverse event | “9 (20.5)” |
| Ascites | “1 (2.3)” |
| Bacteremia | “1 (2.3)” |
| Cancer pain | “1 (2.3)” |
| Cholecystitis | “1 (2.3)” |
| Diarrhea | “1 (2.3)” |
| Fall | “1 (2.3)” |
| Generalized edema | “1 (2.3)” |
| Pulmonary embolism (listed in two rows of the source table) | “1 (2.3)” |
| Pancreatitis acute | “1 (2.3)” |
| Sudden death | “1 (2.3)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-8"></a>

##### First-line cohort: treatment-related serious adverse events

| Serious adverse event related to study drug | Overall population, N = 44, No. (%) |
| --- | --- |
| Any serious adverse event related to study drug | “4 (9.1)” |
| Diarrhea | “1 (2.3)” |
| Pulmonary embolism | “1 (2.3)” |
| Syncope | “1 (2.3)” |
| Sudden death | “1 (2.%)” |

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-9"></a>

##### First-line cohort: hypotension, the most common dose-limiting toxicity of darovasertib monotherapy

> “Hypotension, the most common dose-limiting toxicity observed with darovasertib treatment in the prior phase 1 study,33 occurred in eight patients (18.3%) in this study.”
> “In general, hypotension events occurred early during therapy, with most episodes reported within the first few cycles of treatment. Most hypotension events were mild-to-moderate in severity (grade 1-2), nonserious, and resolved within a short period of time without recurrent events. Only one of these events was ≥grade 3, and there were no reported treatment discontinuations related to hypotension. One patient experienced syncope in association with hypotension early in treatment; this event was resolved shortly thereafter.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-10"></a>

##### First-line cohort: overlapping toxicities of the two agents

> “Therefore, the safety profile was consistent with the known safety profile of the individual agents, although there is some risk of exacerbating some overlapping AEs, such as gastrointestinal AEs, with the combination.”
> “There were no new safety signals identified.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.8.5-11"></a>

##### HLA-A∗02:01-positive expansion, overall population: treatment-related adverse events

| Adverse event | Overall, N = 101, n (%) |
| --- | --- |
| Related adverse event | “101 (100)” |
| Related serious adverse event | “12 (11.9)” |
| Related grade 3 or higher adverse event | “38 (37.6)” |
| Related adverse event leading to discontinuation | “9 (8.9)” |
| Related adverse events leading to reduction | “28 (27.7)” |
| Diarrhea | “83 ( 82.2)” |
| Nausea | “77 ( 76.2)” |
| Edema peripheral | “71 ( 70.3)” |
| Vomiting | “58 ( 57.4)” |
| Fatigue | “55 ( 54.5)” |
| Dizziness | “38 ( 37.6)” |
| Dermatitis acneiform | “35 ( 34.7)” |
| Hypotension | “33 ( 32.7)” |

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

> “The most common treatment-related adverse events (TRAEs) were diarrhea (82%), nausea (76%), peripheral edema (70%), and vomiting (57%)(Table 4)”
> “Grade >3 TRAEs included hypotension (5.9%), syncope (5.9%), and pulmonary embolism (5.0%)”

Source: [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)

<a id="topic-3.1.2.8.5-12"></a>

##### First-line and pretreated cohorts at the expansion dose, safety population: drug-related adverse events

> “In the SP, the most common drug-related adverse events (AEs) (>30%) were diarrhea, nausea, edema, fatigue, hypotension & rash. AEs were largely Grade 1-2. Related Serious AEs were seen in 6 (9%) pts and AEs leading to discontinuation in 4 (6%) pts.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-3.1.2.8.5-13"></a>

##### First-line and pretreated cohorts, 68 participants: drug-related adverse events and serious adverse events

> “The darovasertib and crizotinib combination continued to demonstrate an overall manageable adverse event profile in MUM patients (n=68), with a low rate (10%) of drug-related serious adverse events (SAEs) and limited Grade 4 and Grade 5 SAEs and discontinuations.”
> “31% of patients reported at least one Grade 3 AE; no patients observed a Grade 4 AE; and one patient observed a Grade 5 AE.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-3.1.2.8.5-14"></a>

##### Pretreated cohort, 22 participants: drug-related adverse events

> “The darovasertib and crizotinib combination therapy has a manageable side effect profile in MUM patients (n=22), with a low rate of drug-related serious adverse events (SAE's); predominantly Grade 1 or 2 drug-related adverse events.”
> “Eighteen (18) patients experienced a drug-related AE, of which six (6) patients observed Grade 3, and no patients observed Grade 4 or Grade 5.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

The OptimUM-01 first-line cohort is an open-label, single-arm, nonrandomized expansion of 44 participants, of whom 41 were efficacy-evaluable; the authors describe the data as hypothesis-generating. No formal hypothesis testing was prespecified, and all results were summarized descriptively. Response was assessed by the investigator per RECIST version 1.1. The efficacy-evaluable population required at least one post-baseline tumor assessment, which excluded two participants who discontinued before assessment (one for sudden death) and one ongoing participant; PFS and OS were measured from the first day of treatment in the safety population, and OS is an exploratory end point. The authors state that PFS and OS results are preliminary and that the proportion censored and the medians will change with longer follow-up. Disease control was defined as stable disease lasting at least 8 weeks, where OptimUM-02 required at least 12 weeks. The HLA-A∗02:01 subgroups comprise 29 HLA-A∗02:01-negative and 10 HLA-A∗02:01-positive evaluable participants, and HLA status was unknown for about 5% because testing was not routinely performed at enrollment. Molecular response could be assessed in only the 20 participants with driver mutations reported from tumor tissue. The study reports no quality-of-life or patient-reported outcome results; its end points were safety, ORR, duration of response, disease control rate, PFS, and OS. Comparisons with historical data sets carry, in the authors' words, “the necessary caveats and limitations of cross-study comparisons”.

In the HLA-A∗02:01-positive expansion, response was assessed in an efficacy-evaluable population of participants with at least 3 post-baseline assessments or who discontinued treatment, giving denominators of 11 of 13 treatment-naive and 86 of 101 overall participants. IDEAYA's earlier phase 2 results for 68 participants receiving the combination (data cutoff August 22, 2023) were preliminary and based on investigator review from an unlocked database.

Within the first-line cohort publication, the 95% CIs for median PFS (3.8 to 7.7 months in the results; 5.0 to 8.3 months in the abstract) and median OS (12.5 to 27.1 months; 11.9 to 20.7 months) differ, as do the ORR in HLA-A∗02:01-positive participants (30.0%, 3 of 10, in the subgroup table; 40% in the discussion), the incidence of diarrhea (95.5%; 95.2%), and the incidence of hypotension (18.3%; 18.2%).

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802); [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385); [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf); [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503); [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-3.1.2.9-2"></a>

#### First-line cohort: open-label, single-arm design and immature survival data

> “Limitations include that this is an open-label, single-arm study, so the data presented should be considered hypothesis-generating. In addition, the results for PFS and OS analysis are considered preliminary; the proportion of patients censored and median OS and PFS results will continue to mature with longer follow-up.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.9-3"></a>

#### First-line cohort: cross-study comparisons with historical data

> “With the necessary caveats and limitations of cross-study comparisons, the PFS and OS results of this study are encouraging relative to the outcomes reported in relevant historical data sets for patients with mUM.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.9-4"></a>

#### First-line cohort: molecular response limited to participants with known tumor driver mutations

> “Patients without available information about driver mutations from tumor tissue were unable to be assessed for molecular response.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-3.1.2.9-5"></a>

#### Efficacy by HLA-A2 serotype from a preliminary analysis of an unlocked database as of August 22, 2023

> “The reported efficacy data by HLA-A2 serotype was based on a preliminary analysis of an unlocked database as of August 22, 2023 by investigator review and RECIST 1.1.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
